Tu1818 – Ultra-Proactive Therapeutic Drug Monitoring Incorporating Infliximab Point-Of-Care Testing with Ad Hoc Dose Adjustment Reduces C-Reactive Protein Levels in Patients with IBD During Infliximab Maintenance Treatment

2019 ◽  
Vol 156 (6) ◽  
pp. S-1136 ◽  
Author(s):  
Peter Bossuyt ◽  
Eveline Hoefkens ◽  
Inge Geerts ◽  
Freija Verbiest ◽  
Edith Vermeulen ◽  
...  
2014 ◽  
Vol 433 ◽  
pp. 145-149 ◽  
Author(s):  
Kazuhiko Kotani ◽  
Takaomi Minami ◽  
Toshiaki Abe ◽  
Junji Sato ◽  
Nobuyuki Taniguchi ◽  
...  

2020 ◽  
Vol 12 (1) ◽  
pp. 1-7
Author(s):  
Simon Searle-Barnes ◽  
Peter Phillips

Acute cough is one of the most common illnesses in the UK, with an estimated 48 million cases per annum. The majority of these presentations are thought to be of viral aetiology and self-limiting in nature, yet some studies report antibiotic prescription rates of approximately 65% in the UK. Clincians' decision-making process can be influenced by both patient expectations and difficulty in differentiating between viral and bacterial aetiologies by clinical examination alone. This article will consider the feasibility, efficacy, benefits and limitations of using point-of-care testing of C-reactive protein within primary care in the United Kingdom to help inform management of acute cough.


2018 ◽  
Vol 202 ◽  
pp. 1-12 ◽  
Author(s):  
Marco J. Haenssgen ◽  
Nutcha Charoenboon ◽  
Thomas Althaus ◽  
Rachel C. Greer ◽  
Daranee Intralawan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document